Producción Científica UPeU

URI permanente para esta comunidadhttps://cris.upeu.edu.pe/handle/123456789/1

Examinar

Ajustes

Autor/a: search.filters.author.Daniel Bunout

Resultados de la búsqueda

Mostrando 1 - 10 de 14
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Effects of Ethanol on Hepatic Blood Flow in the Rat
    (1981-03-01)
    H Iturriaga
    ;
    Daniel Bunout
    ;
    Margarita Petermanri
    ;
    ;
    Yedi Israel
    Hepatic blood flow measured by indocyanine green clearance was studied in rats after an acute intoxicating dose of ethanol (2 g/kg) or after chronic ethanol administration by feeding with alcohol liquid diets. Acute intoxication to normal animals did not modify hepatic blood flow. In chronically alcohol-fed rats, hepatic blood flow was significantly decreased when measured after 15 hr of abstinence. If ethanol was not withdrawn and an acute dose of ethanol was given before the indocyanine green clearance, a decreased hepatic blood flow was not observed. It is suggested that the reduction of hepatic blood flow in recently abstinent chronically alcohol-treated animals is related to the withdrawal syndrome.
      17
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Nutritional status of alcoholic patients: it's possible relationship to alcoholic liver damage
    (1983-09-01)
    Daniel Bunout
    ;
    V Gattás
    ;
    H Iturriaga
    ;
    Carla Perez
    ;
    T Pereda
      52
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Content of Hepatic Reduced Glutathione in Chronic Alcoholic Patients: Influence of the Length of Abstinence and Liver Necrosis
    (1984-03-01)
    Luis A. Videla
    ;
    H Iturriaga
    ;
    María Eugenia Pino
    ;
    Daniel Bunout
    ;
    Alfonso Valenzuela
    1. The relationship between the content of hepatic reduced glutathione (GSH) and the length of abstinence was investigated in 45 chronic alcoholic patients. 2. Hepatic GSH levels were significantly correlated (r = 0.58; P<0.001) with the length of alcohol withdrawal in the whole group. According to liver histology patients were divided into two groups, with and without hepatic necrosis. Subjects without necrosis showed a significant positive correlation (r = 0.71; P<0.001) between GSH values and the length of abstinence; no correlation (r = −0.22; P<0.40) was observed in the group with necrosis. 3. According to the period of abstinence patients were separated into two groups, with a short (≪ 5 days) and a prolonged (> 5 days) alcohol withdrawal. Patients with and without necrosis exhibited comparable mean levels of liver GSH (2.04 ± sem 0.21 and 1.74 ± 0.23 μmol/g respectively; P<0.30) when studied after short periods of abstinence. Alcoholics without liver necrosis showed significantly higher hepatic GSH levels than those with necrosis (3.23 ± 0.30 and 1.60 ± 0.33 respectively; P < 0.01) after prolonged periods of alcohol withdrawal. Similar results were obtained when liver GSH levels were expressed as a function of the mean surface area of hepatocytes, which was not significantly different between patients with and without hepatic necrosis. 4. Parameters assessing the nutritional status of patients with and without necrosis were not significantly different. Steatosis, histologically scored and irrespective of the period of abstinence, was higher in patients with liver necrosis and it did not correlate with hepatic GSH (r = −0.17; not significant). Fibrosis was observed in 20 cases and it did not modify the positive correlation between liver GSH content and the period of abstinence (with fibrosis: r = 0.57; P < 0.01; without fibrosis: r = 0.58;P < 0.01). 5. The changes observed in liver GSH content might be of pathogenic importance in alcoholic liver disease through alterations in lipoperoxidative processes in the hepatocyte.
      46
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    [Serum levels of thyroid hormones in alcoholic subjects without hepatic insufficiency].
    (1985-08-01)
    Daniel Bunout
    ;
    Daniel Ñañez Del Pino
    ;
    H Iturriaga
    ;
    R Barrera
    ;
    Carlos A. Perez
    Etude faite chez des sujets qui viennent recemment de s'arreter de boire. On note une correlation negative entre le metabolisme de l'ethanol et les taux de triiodothyronine. Les mecanismes qui produisent ces resultats ne sont pas clairs mais plusieurs hypotheses sont avancees
      1
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Glucose tolerance and the insulin response in recently drinking alcoholic patients: Possible effects of withdrawal
    (1986-03-01)
    H Iturriaga
    ;
    Melani R. Kelly
    ;
    Daniel Bunout
    ;
    María Eugenia Pino
    ;
    T Pereda
      16
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Nitrogen economy in alcoholic patients without liver disease
    (1987-07-01)
    Daniel Bunout
    ;
    Marcus Petermann
    ;
    ;
    G Barrera
    ;
    H Iturriaga
      30
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Glucose Turnover Rate and Peripheral Insulin Sensitivity in Alcoholic Patients without Liver Damage
    (1989-01-01)
    Daniel Bunout
    ;
    Marcus Petermann
    ;
    M. Bravo
    ;
    Mary M. Kelly
    ;
    S Hirsch
    Glucose intolerance is frequently found in alcoholic patients and an impaired insulin response has been documented in them. To look for alternative mechanisms that could explain this intolerance, a glucose turnover using tritiated glucose and an euglycemic glucose clamp were performed to measure the glucose production rate and peripheral insulin sensitivity, respectively. Two groups of recently abstinent chronic male alcoholic patients without evidence of liver damage were studied. The glucose turnover technique showed a higher basal glucose production rate in alcoholics, compared with normal volunteers (2.83 +/- 0.29 vs. 1.84 +/- 0.22 mg/kg/min); an intravenous ethanol load significantly increased this rate. The euglycemic glucose clamp did not show peripheral insulin resistance in alcoholics, compared with controls.
      14
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Nutritional support in hospitalized patients with alcoholic liver disease.
    (1989-09-01)
    Daniel Bunout
    ;
    V Aicardi
    ;
    Sandra Hirsch
    ;
    Marcus Petermann
    ;
    Matt Kelly
    The effects of a nutritional support in hospitalized patients with alcoholic cirrhosis and liver failure were studied in a controlled protocol. Thirty-six patients were included, 17 were randomly assigned to an experimental group and the rest to a control group. Experimentals received a diet aiming at 50 kcal (209 kJ)/kg bodyweight/d and 1.5 g protein/kg bodyweight/d (as proteins of high biological value). Controls received the standard diet prescribed by the attending physician. The severity of liver failure and the nutritional status on admission were similar in both groups. The measured energy intake in controls was 1813 +/- 121 kcal/d (7589 +/- 506 kJ/d) and 2707 +/- 71 kcal/d (1131 +/- 297 kJ/d) in experimentals (P less than 0.001). The protein intake in controls was 47 +/- 3.8 g/d and in experimentals 80 +/- 3 g/d (P less than 0.001). There were seven deaths during the study period (two experimentals and five controls). No differences were observed in the evolution of liver failure, hepatic encephalopathy or nutritional status between both study groups. It is concluded that a higher energy and protein intake in these patients does not have adverse effects and is associated with a non-significant reduction in mortality.
      77
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    [Controlled study of the effect of silymarin on alcoholic liver disease].
    (1992-12-01)
    Daniel Bunout
    ;
    Sandra Hirsch
    ;
    Marcus Petermann
    ;
    María Pía de la Maza
    ;
    G Silva
    A controlled trial on the use of Silymarin in patients with alcoholic liver disease was performed. Seventy two patients were admitted to the trial and randomly assigned to an experimental or controls group. Experimentals received 280 mg/day of Silymarin and controls an equal number of placebo tablets. Three patients on placebo and nine on Silymarin were lost from control (p = 0.035), remaining in control 34 patients receiving placebo and 25 patients receiving the drug. Both groups did not differ in their initial laboratory assessment and were followed up for an average of 15 months. Ten patients died during the follow up (5 in placebo and 5 in Silymarin); life table analysis did not show significant differences in mortality. Patients who died had lower serum albumin and prothrombin time and higher total bilirubin, alkaline phosphatases and CCLI on the initial clinical and laboratory assessment. Final laboratory values and their changes in those who survived did not differ between Silymarin and placebo. Twenty two patients on placebo (65%) and 14 on Silymarin (58%) recognized alcohol ingestion or had a positive urine sample analysis for alcohol during follow up. Those who abstained from alcohol had a significant fall in gamma glutamyl transferase during follow up. No other significant differences were observed between these two groups. It is concluded that in this trial, Silymarin did not change the evolution or mortality of alcoholic liver disease.
      32
  • Publicacion
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publicación,
    Controlled Trial on Nutrition Supplementation in Outpatients With Symptomatic Alcoholic Cirrhosis
    (1993-03-01)
    Sandra Hirsch
    ;
    Daniel Bunout
    ;
    Pı́a de la Maza
    ;
    H Iturriaga
    ;
    Margarita Petermann
    A controlled trial on nutrition supplementation in ambulatory patients with decompensated alcoholic liver disease was carried out during 1 year. Fifty-one patients were studied; 26 were assigned to an experimental group receiving a daily supplement of 1000 kcal and 34 g of proteins given as a casein-based enteral nutrition product and 25 to a control group receiving one placebo capsule. Patients were examined in a special clinic once a month or more if required. Sixty-eight percent of patients admitted to alcohol ingestion or had alcohol in urine samples on at least one occasion. Dietary recalls showed a significantly higher protein and caloric intake in case patients subjects (p < .0001). Nine patients died during the study, three case patients and six control patients (p = NS). The frequency of hospitalizations was significantly less in the experimental group. This difference was attributed to a reduction in severe infections. Mid-arm circumference, serum albumin concentration, and hand grip strength improved earlier in case patients, although both groups had a significant improvement in these parameters. Bilirubin and aspartate aminotransferase decreased and prothrombin time increased significantly in both groups during the study period, without differences between groups. It is concluded that nutrition support decreases nutrition-associated complications in patients with alcoholic liver disease.
      168